Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy
This article was originally published in Start Up
Executive Summary
A year ago, Clovis Oncology secured $145 million in start-up financing, the largest A round ever for a biotech. Now, the firm has mapped out a potential clinical trials and approval track for its first therapeutics program. And under a deal announced in April, development of that first drug, a lipid-conjugated formulation of the chemotherapy drug gemcitabine, will include a companion diagnostic developed and sold by Ventana Medical Systems.
You may also be interested in...
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Start-Up Quarterly Statistics, Q2 2010
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.